Hereditary angioedema (HAE) in children and adolescents-a consensus on therapeutic strategies

European Journal of Pediatrics

Volumn 171, Issue 9, 2012, Pages 1339-1348

  Wahn, V ^a   Aberer, W ^b   Eberl, W ^c   Fasshauer M ^d   Kuhne T ^e   Kurnik, K ^f   Magerl, M ^a   Meyer Olson, D ^g   Martinez Saguer, I ^h   Spath P ⁱ   Staubach Renz, P ^j   Kreuz, W ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c City Hospital   (Germany)

^d Klinikum St Georg   (Germany)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

C1 INH (C1 inhibitor, C1 esterase inhibitor); Consensus; Hereditary angioedema; Pediatric

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; CONSENSUS DEVELOPMENT; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GERMANY; HEADACHE; HUMAN; INJECTION SITE REACTION; NAUSEA; PEDIATRICIAN; PEDIATRICS; PRIORITY JOURNAL; PROPHYLAXIS; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANDROGENS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; AUSTRIA; BRADYKININ; CHILD; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT INACTIVATING AGENTS; DISEASE PROGRESSION; GERMANY; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; PEPTIDES; RECOMBINANT PROTEINS; SWITZERLAND;

EID: 84865970425     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1726-4     Document Type: Article

References (35)

1. Bork K, Hardt J (2009) Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 122:780-783
2. Bork K, Hardt J, Schicketanz KH, Ressel N (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229-1235
3. Bork K, Hardt J, Staubach-Renz P, Witzke G (2011) Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:58-64
4. Bork K, Siedlecki K, Bosch S et al (2000) Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 75:349-354
5. Bowen T (2011) Hereditary angioedema: beyond international consensus-circa December 2010-the Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy asthma. Clin Immunol 7:1
6. Bowen T, Cicardi M, Farkas H et al (2010) 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24
7. Boyle RJ, Nikpour M, Tang MLK (2005) Hereditary angioedema in children: a management guideline. Pediatr Allergy Immunol 16:288-294
8. Cicardi M, Banerji A, Bracho F et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532-541
9. Cicardi M, Bork K, Caballero T et al (2012) Evidence-based recommendations for therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67:147-157
10. Cicardi M, Levy RJ, McNeil DL et al (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523-531
11. Cinryze. Summary of product characteristics. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001207/WC500108895.pdf. Accessed 13 March 2012
12. Craig TJ, Bewtra AK, Bahna SL et al (2011) C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-final results of the IMPACT 2 study. Allergy 66:1604-1611
13. Craig TJ, Levy RJ, Wasserman RL et al (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attack. J Allergy Clin Immunol 124:801-808
14. De Serres J, Gröner A, Lindner J (2003) Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 29:247-254
15. Farkas H, Harmat G, Gyeney L, Füst G, Varga L (1999) Danazol therapy for hereditary angio-oedema in children. Lancet 354: 1031-1032
16. Farkas H, Jakab L, Temesszentandrási G et al (2007) Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 120:941-947
17. Frank MM, Jiang H (2008) New therapies for angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 121:272-280
18. Frank MM, Sergent JS, Kane MA, Alling DW (1972) Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 286:808-812
19. Garnock-Jones KP (2010) Ecallantide: in acute hereditary angioedema. Drugs 70:1423-1431
20. Gwynn CM (1974) Therapy in hereditary angioneurotic oedema. Arch Dis Child 49:636-640
21. Kalbitor. United States prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125277lbl.pdf. Accessed 13 March 2012
22. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Klingebiel T (2012) Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 52:100-107
23. Levy JH, Freiberger DJ, Roback J (2010) Hereditary angioedema: current and emerging treatment options. Anesth Analg 110:1271-1280
24. Levy RJ, Lumry WR, McNeil DL et al (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523-529
25. LonghurstHJ, Farkas H, Craig TJ et al (2010)HAE international home therapy consensus document. Allergy Asthma Clin Immunol 6:22
26. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, von Hentig N, Klingebiel T, Kreuz W (2010) Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 50:354-360
27. Maurer M, Magerl M (2010) Hereditary angioedema: an update on available therapeutic options. J Dtsch Dermatol Ges 8:663-672
28. Maurer M, Magerl M (2011) Long-term prophylaxis of hereditary angioedema with androgen derivatives: a critical appraisal and potential alternatives. J Dtsch Dermatol Ges 9:99-107
29. Sheffer AL, Austen KF, Rosen FS (1972) Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287:452-454
30. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE (2011) Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 128:153-159
31. Tallroth GA (2011) Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. IntArch Allergy Immunol 154:356-359
32. Zanichelli A, Vachini R, Badini M, Penna V, Cicardi M (2011) Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 66:192-196
33. Zuraw BL (2008) Hereditary angioedema. N Engl J Med 359:1027-1036
34. Zuraw BL, Busse PJ, White M et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513-522
35. Zuraw BL, Cicardi M, Levy RJ et al (2010) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821-827